9/22/2021 8:58:12 AM
CLRB : Iopofosine I-131- External Beam Radiation Data Suggests Safety And Tolerability InRefractory Head And Neck Cancer
8/18/2021 8:33:15 AM
Cellectar Granted $2 Mln Phase II NIH SBIR Grant To Support Study Of Iopofosine I-131 In Waldenstrom’s Macroglobulinemia
7/12/2021 8:35:31 AM
Cellectar Announces Co-Development And Commercialization Collaboration With LegoChemBio
1/27/2021 8:42:44 AM
Cellectar Gets Orphan Drug Designation From EMA For CLR 131 In Waldenstrom's Macroglobulinemia
11/9/2020 8:48:33 AM
Cellectar Q3 Net Loss Attributable $3.9 Mln Or $0.15/Shr Vs Loss $3.9 Mln Or $0.42/Shr Last Year
7/1/2020 8:13:59 AM
Cellectar Biosciences Appoints John Friend As Chief Medical Officer
6/3/2020 9:06:09 AM
Cellectar Biosciences Reports Pricing Of $20 Mln Underwritten Public Offering
5/26/2020 7:54:32 AM
Cellectar Biosciences Secures FDA Fast Track Designation For CLR 131
1/7/2020 8:21:14 AM
Cellectar Names Igor Grachev Chief Medical Officer
1/6/2020 8:24:31 AM
Cellectar Biosciences Secures Orphan Drug Designation For CLR 131 In Lymphoplasmacytic Lymphoma